Twenty-first Century Trends in the Global Epidemiology of Pediatric-Onset Inflammatory Bowel Disease: Systematic Review

Gastroenterology, Journal Year: 2022, Volume and Issue: 162(4), P. 1147 - 1159.e4

Published: Jan. 5, 2022

The incidence of inflammatory bowel disease (IBD) is increasing internationally, particularly in nations with historically low rates. Previous reports the epidemiology pediatric-onset IBD identified a paucity data. We systematically reviewed global trends and prevalence diagnosed individuals <21 years old over first 2 decades 21st century.We studies indexed MEDLINE, EMBASE, Airiti Library, SciELO from January 2010 to February 2020 identify population-based reporting and/or IBD, Crohn's disease, ulcerative colitis, IBD-unclassified. Data published before 2000 were derived previously systematic review. described geographic distribution children all ages limiting very early onset (VEO) IBD.A total 131 48 countries included. highest Northern Europe North America lowest Southern Europe, Asia, Middle East. Among evaluating time, most (31 37, 84%) reported significant increases (7 7) prevalence. on VEO-IBD are limited high rates IBD. Time visually heterogeneous.Rates continue rise around world data emerging regions where it was not reported; however, there remains pediatric developing recently developed countries.

Language: Английский

---

Global, regional and national burden of inflammatory bowel disease in 204 countries and territories from 1990 to 2019: a systematic analysis based on the Global Burden of Disease Study 2019

BMJ Open, Journal Year: 2023, Volume and Issue: 13(3), P. e065186 - e065186

Published: March 1, 2023

We aimed to provide the most updated estimates on global burden of inflammatory bowel disease (IBD) improve management strategies.We extracted data from Global Burden Disease (GBD) 2019 database evaluate IBD with different measures in 204 countries and territories 1990 2019.Studies GBD generated by population-representative sources identified through a literature review research collaborations were included.Patients an diagnosis.Total numbers, age-standardised rates prevalence, mortality disability-adjusted life-years (DALYs), their estimated annual percentage changes (EAPCs) main outcomes.In 2019, there approximately 4.9 million cases worldwide, China USA having highest number (911 405 762 890 (66.9 245.3 per 100 000 people, respectively)). Between deaths DALYs decreased (EAPCs=-0.66,-0.69 -1.04, respectively). However, prevalence rate increased 13 out 21 regions. A total 147 or experienced increase rate. From prevalent cases, higher among females than males. Socio-demographic Index was associated rates.IBD will continue be major public health due increasing numbers DALYs. The epidemiological trends have changed dramatically at regional national levels, so understanding these would beneficial for policy makers tackle IBD.

Language: Английский

---

Ulcerative Colitis in Adults

JAMA, Journal Year: 2023, Volume and Issue: 330(10), P. 951 - 951

Published: Sept. 12, 2023

Importance Ulcerative colitis (UC) is a chronic inflammatory condition of the colon, with prevalence exceeding 400 per 100 000 in North America. Individuals UC have lower life expectancy and are at increased risk for colectomy colorectal cancer. Observations impairs quality secondary to inflammation colon causing diarrhea rectal bleeding. Extraintestinal manifestations, such as primary sclerosing cholangitis, occur approximately 27% patients UC. People require monitoring symptoms biomarkers (eg, fecal calprotectin), colonoscopy 8 years from diagnosis surveillance dysplasia. Risk stratification by disease location Montreal Classification) activity Mayo Score) can guide management First-line therapy induction maintenance remission mild moderate 5-aminosalicylic acid. Moderate severe may oral corticosteroids bridge medications that sustain (biologic monoclonal antibodies against tumor necrosis factor [eg, infliximab], α4β7 integrins [vedolizumab], interleukin [IL] 12 IL-23 [ustekinumab]) small molecules inhibit janus kinase tofacitinib) or modulate sphingosine-1-phosphate (ozanimod). Despite advances medical therapies, highest response these treatments ranges 30% 60% clinical trials. Within 5 diagnosis, 20% hospitalized 7% undergo colectomy. The cancer after 20 duration 4.5%, people 1.7-fold higher compared general population. Life 80.5 females 76.7 males, which shorter than without Conclusions Relevance affects every An effective treatment acid, whereas be treated advanced therapies target specific pathways, including factor, integrins, IL-12 cytokines, well molecule targeting sphingosine-1-phosphate.

Language: Английский

---

TRP (transient receptor potential) ion channel family: structures, biological functions and therapeutic interventions for diseases

Signal Transduction and Targeted Therapy, Journal Year: 2023, Volume and Issue: 8(1)

Published: July 5, 2023

Abstract Transient receptor potential (TRP) channels are sensors for a variety of cellular and environmental signals. Mammals express total 28 different TRP channel proteins, which can be divided into seven subfamilies based on amino acid sequence homology: TRPA (Ankyrin), TRPC (Canonical), TRPM (Melastatin), TRPML (Mucolipin), TRPN (NO-mechano-potential, NOMP), TRPP (Polycystin), TRPV (Vanilloid). They class ion found in numerous tissues cell types permeable to wide range cations such as Ca 2+ , Mg Na + K others. responsible various sensory responses including heat, cold, pain, stress, vision taste activated by number stimuli. Their predominantly location the surface, their interaction with physiological signaling pathways, unique crystal structure make TRPs attractive drug targets implicate them treatment diseases. Here, we review history discovery, summarize structures functions family, highlight current understanding role pathogenesis human disease. Most importantly, describe channel-related therapeutic interventions diseases limitations targeting clinical applications.

Language: Английский

---

The metabolic nature of inflammatory bowel diseases

Nature Reviews Gastroenterology & Hepatology, Journal Year: 2022, Volume and Issue: 19(12), P. 753 - 767

Published: July 29, 2022

Language: Английский

---

Global Hospitalization Trends for Crohn’s Disease and Ulcerative Colitis in the 21st Century: A Systematic Review With Temporal Analyses

Clinical Gastroenterology and Hepatology, Journal Year: 2022, Volume and Issue: 21(9), P. 2211 - 2221

Published: July 19, 2022

Background & AimsThe evolving epidemiologic patterns of inflammatory bowel disease (IBD) throughout the world, in conjunction with advances therapeutic treatments, may influence hospitalization rates IBD. We performed a systematic review temporal analysis for IBD across world 21st century.MethodsWe systematically reviewed Medline and Embase population-based studies reporting IBD, Crohn's (CD), or ulcerative colitis (UC) century. Log-linear models were used to calculate average annual percentage change (AAPC) associated 95% confidence intervals (95% CIs). Random-effects meta-analysis pooled country-level AAPCs. Data stratified by stage region: compounding prevalence (stage 3) North America, Western Europe, Oceania vs acceleration incidence 2) Asia, Eastern Latin America emergence 1) developing countries.ResultsHospitalization primary diagnosis stable countries 3 (AAPC, −0.13%; CI, −0.72 0.97), CD 0.20%; −1.78 2.17), UC 0.02%; −0.91 0.94). In contrast, increasing 2 4.44%; 2.75 6.14), 8.34%; 4.38 12.29), 3.90; 1.29 6.52). No available regions 1 (emergence).ConclusionsHospitalization are stabilizing 3, whereas newly industrialized have rapidly rates, contributing an burden on global health care systems. The countries. Hospitalization (emergence).

Language: Английский

---

Macrophages in intestinal homeostasis and inflammatory bowel disease

Nature Reviews Gastroenterology & Hepatology, Journal Year: 2023, Volume and Issue: 20(8), P. 538 - 553

Published: April 17, 2023

Language: Английский

---

Incidence, Prevalence, and Racial and Ethnic Distribution of Inflammatory Bowel Disease in the United States

Gastroenterology, Journal Year: 2023, Volume and Issue: 165(5), P. 1197 - 1205.e2

Published: July 20, 2023

Language: Английский

---

Exosome-based bone-targeting drug delivery alleviates impaired osteoblastic bone formation and bone loss in inflammatory bowel diseases

Cell Reports Medicine, Journal Year: 2023, Volume and Issue: 4(1), P. 100881 - 100881

Published: Jan. 1, 2023

Systematic bone loss is commonly complicated with inflammatory bowel diseases (IBDs) unclear pathogenesis and uncertain treatment. In experimental colitis mouse models established by dextran sulfate sodium IL-10 knockout induced piroxicam, mass quality are significantly decreased. Colitis mice demonstrate a lower formation rate fewer osteoblasts in femur. Bone marrow mesenchymal stem/stromal cells (BMSCs) from tend to differentiate into adipocytes rather than osteoblasts. Serum patients IBD promotes adipogenesis of human BMSCs. RNA sequencing reveals that downregulates Wnt signaling For treatment, exosomes Golgi glycoprotein 1 inserted could carry agonist accumulate via intravenous administration. They alleviate loss, promote formation, accelerate fracture healing mice. Collectively, BMSC commitment microenvironment contributes quantity be rescued redirecting differentiation toward through bone-targeted drug delivery.

Language: Английский

---

Oxidative stress, hormones, and effects of natural antioxidants on intestinal inflammation in inflammatory bowel disease

Frontiers in Endocrinology, Journal Year: 2023, Volume and Issue: 14

Published: Aug. 28, 2023

Inflammatory bowel disease (IBD) is a chronic, relapsing gastrointestinal (GI) disorder characterized by intestinal inflammation. The etiology of IBD multifactorial and results from complex interplay between mucosal immunity, environmental factors, host genetics. Future therapeutics for GI disorders, including IBD, that are driven oxidative stress require greater understanding the cellular molecular mechanisms mediated reactive oxygen species (ROS). In tract, stressors include infections pro-inflammatory responses, which boost ROS generation promoting production cytokines. Nuclear factor kappa B (NF-κB) nuclear erythroid 2–related 2 (Nrf2) represent two important signaling pathways in immune cells regulate numerous physiological processes, anti-inflammatory antioxidant activities. Natural compounds exhibit scavenging increase defense capacity to inhibit pro-oxidative enzymes, may be useful treatment. this review, we discuss various polyphenolic substances (such as resveratrol, curcumin, quercetin, green tea flavonoids, caffeic acid phenethyl ester, luteolin, xanthohumol, genistein, alpinetin, proanthocyanidins, anthocyanins, silymarin), phenolic thymol, alkaloids such berberine, storage polysaccharides tamarind xyloglucan, other phytochemicals represented isothiocyanate sulforaphane food/spices ginger, flaxseed oil), well hormones like melatonin target reduce inflammation occurring with IBD.

Language: Английский

---